Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor [PDF]
Journal of Hematology & Oncology, 2016 More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic ...
Jingjing Wu, Mingzhi Zhang, Delong Liu
doaj +2 more sources
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice [PDF]
Frontiers in Oncology, 2021 Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small ...
Susan M. O’Brien +6 more
doaj +3 more sources
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy [PDF]
Haematologica, 2022 Strategies to overcome resistance to FMS-like tyrosine kinase 3 (FLT3)-targeted therapy in acute myeloid leukemia (AML) are urgently needed.
Weiguo Zhang +14 more
doaj +2 more sources
Scientific Reports, 2017 BTK plays a critical role in the B cell receptor mediated inflammatory signaling in the rheumatoid arthritis (RA). Through a rational design approach we discovered a highly selective and potent BTK kinase inhibitor (CHMFL-BTK-11) which exerted its ...
Hong Wu +21 more
doaj +2 more sources
BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?
, 2022 The development of BTK inhibitors has revolutionized the management of CLL. Currently, there are 3 BTK inhibitors available to treat CLL: ibrutinib, acalabrutinib, and zanubrutinib (the latter not yet approved for this disease but included in the NCCN ...
Venugopal, Sangeetha +2 more
core +4 more sources
eLifeInhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor
Raji E Joseph +7 more
doaj +2 more sources
Phylogeny of Tec Family Kinases: Identification of a Pre-Metazoan Origin of Btk, Bmx, Itk, Tec, Txk and the Btk Regulator SH3BP5 [PDF]
, 2008 It is generally considered mammals and birds have five Tec family kinases (TFKs): Btk, Bmx (also known as Etk), Itk, Tec, and Txk (also known as Rlk). Here, we discuss the domains and their functions and regulation in TFKs.
Ortutay, Csaba +3 more
core +2 more sources
Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
Cells, 2022 Bruton’s Tyrosine Kinase (BTK) is considered crucial in the activation and survival of both physiological and malignant B-cells. In recent years, ibrutinib, an oral BTK inhibitor, became a breakthrough therapy for hematological malignancies, such as ...
Katarzyna Szklener +4 more
doaj +1 more source
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas [PDF]
Acta Pharmacologica SinicaHua Xie
exaly +2 more sources
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Molecules, 2021 Bruton’s tyrosine kinase (BTK) plays a crucial role in B-cell receptor and Fc receptor signaling pathways. BTK is also involved in the regulation of Toll-like receptors and chemokine receptors.
Datong Zhang, He Gong, Fancui Meng
doaj +1 more source